StreetInsider.com News Articles

NurExone to Showcase Its Regenerative Medicine Platform at NANO.IL.2026 and Advanced Therapies Congress in March 2026 and Provides Corporate Update

Fri, 27 Feb 2026 16:03:00 +0000

TORONTO and HAIFA, Israel, Feb. 27, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, announced today its participation in two international conferences taking place in March 2026.

Dr. Lior Shaltiel, PhD, Chief Executive Officer of NurExone, commented, “Engaging with scientific, industry, and investor audiences is a core part of our strategy, and March includes two important forums. For NurExone, NANO.IL.2026 and Advanced Therapies represent two sides of the same innovation pathway - one focused on nano scale biology and

NurExone to Showcase Its Regenerative Medicine Platform at NANO.IL.2026 and Advanced Therapies Congress in March 2026 and Provides Corporate Update

Fri, 27 Feb 2026 16:03:00 +0000

NurExone to Showcase Its Regenerative Medicine Platform at NANO.IL.2026 and Advanced Therapies Congress in March 2026 and Provides Corporate Update

Fri, 27 Feb 2026 16:03:00 +0000

NurExone to Showcase Its Regenerative Medicine Platform at NANO.IL.2026 and Advanced Therapies Congress in March 2026 and Provides Corporate Update

Fri, 27 Feb 2026 16:03:00 +0000

NurExone to Showcase Its Regenerative Medicine Platform at NANO.IL.2026 and Advanced Therapies Congress in March 2026 and Provides Corporate Update

Fri, 27 Feb 2026 16:03:00 +0000

NurExone to Showcase Its Regenerative Medicine Platform at NANO.IL.2026 and Advanced Therapies Congress in March 2026 and Provides Corporate Update

Fri, 27 Feb 2026 16:03:00 +0000

NurExone to Showcase Its Regenerative Medicine Platform at NANO.IL.2026 and Advanced Therapies Congress in March 2026 and Provides Corporate Update

Fri, 27 Feb 2026 16:03:00 +0000

NurExone to Showcase Its Regenerative Medicine Platform at NANO.IL.2026 and Advanced Therapies Congress in March 2026 and Provides Corporate Update

Fri, 27 Feb 2026 16:03:00 +0000

NurExone to Showcase Its Regenerative Medicine Platform at NANO.IL.2026 and Advanced Therapies Congress in March 2026 and Provides Corporate Update

Fri, 27 Feb 2026 16:03:00 +0000

NurExone to Showcase Its Regenerative Medicine Platform at NANO.IL.2026 and Advanced Therapies Congress in March 2026 and Provides Corporate Update

Fri, 27 Feb 2026 16:03:00 +0000

NurExone to Showcase Its Regenerative Medicine Platform at NANO.IL.2026 and Advanced Therapies Congress in March 2026 and Provides Corporate Update

Fri, 27 Feb 2026 16:03:00 +0000

NurExone to Showcase Its Regenerative Medicine Platform at NANO.IL.2026 and Advanced Therapies Congress in March 2026 and Provides Corporate Update

Fri, 27 Feb 2026 16:03:00 +0000

NurExone Reports Anti-Inflammatory Activity of Its Exosomes in Lab Analysis

Fri, 19 Dec 2025 16:04:00 +0000

TORONTO and HAIFA, Israel, Dec. 19, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) today announced new laboratory data demonstrating that its proprietary exosomes can significantly reduce inflammatory activity compared to untreated cells and cells treated with a commercially available exosome product.

“Inflammation and regeneration are conflicting biological processes, and this is particularly relevant in the Central Nervous System,” said Dr. Tali Kizhner, Director of Research & Development at NurExone. “These laboratory results show that our exosomes suppress inflammation more effectively than untreated cells and commercial

NurExone Reports Anti-Inflammatory Activity of Its Exosomes in Lab Analysis

Fri, 19 Dec 2025 16:04:00 +0000

NurExone Reports Anti-Inflammatory Activity of Its Exosomes in Lab Analysis

Fri, 19 Dec 2025 16:04:00 +0000

NurExone Reports Anti-Inflammatory Activity of Its Exosomes in Lab Analysis

Fri, 19 Dec 2025 16:04:00 +0000

NurExone Reports Anti-Inflammatory Activity of Its Exosomes in Lab Analysis

Fri, 19 Dec 2025 16:04:00 +0000

NurExone Reports Anti-Inflammatory Activity of Its Exosomes in Lab Analysis

Fri, 19 Dec 2025 16:04:00 +0000

NurExone Reports Anti-Inflammatory Activity of Its Exosomes in Lab Analysis

Fri, 19 Dec 2025 16:04:00 +0000

NurExone Reports Anti-Inflammatory Activity of Its Exosomes in Lab Analysis

Fri, 19 Dec 2025 16:04:00 +0000

NurExone Secures over C$3.18 Million Through Accelerated Warrant Exercises

Wed, 12 Nov 2025 16:02:00 +0000

TORONTO and HAIFA, Israel, Nov. 12, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) is pleased to announce that, further to its press release dated October 8, 2025 (the “October 8 Release”), the Company has received gross proceeds of over C$3.18M through accelerated warrant exercises.

The breakdown of the proceeds is as follows: (i) C$1,207,418.88 through the exercise of 2,515,456 September 2023 Warrants at a price of C$0.48 per September 2023 Warrant issued from a non-brokered private placement which closed in tranches on August

NurExone Secures over C$3.18 Million Through Accelerated Warrant Exercises

Wed, 12 Nov 2025 16:02:00 +0000

NurExone Secures over C$3.18 Million Through Accelerated Warrant Exercises

Wed, 12 Nov 2025 16:02:00 +0000

NurExone Secures over C$3.18 Million Through Accelerated Warrant Exercises

Wed, 12 Nov 2025 16:02:00 +0000

NurExone Secures over C$3.18 Million Through Accelerated Warrant Exercises

Wed, 12 Nov 2025 16:02:00 +0000